INVIVO THERAPEUTICS HOLDINGS (NVIV)

US46186M6057 - Common Stock

0.3207  -0.17 (-34.28%)

After market: 0.231 -0.09 (-27.97%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVIV. NVIV was compared to 195 industry peers in the Health Care Equipment & Supplies industry. NVIV has a great financial health rating, but its profitability evaluates not so good. NVIV does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

In the past year NVIV has reported negative net income.
In the past year NVIV has reported a negative cash flow from operations.
NVIV had negative earnings in each of the past 5 years.
NVIV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -97.39%, NVIV is doing worse than 82.32% of the companies in the same industry.
NVIV has a Return On Equity of -104.60%. This is in the lower half of the industry: NVIV underperforms 71.21% of its industry peers.
Industry RankSector Rank
ROA -97.39%
ROE -104.6%
ROIC N/A
ROA(3y)-47.54%
ROA(5y)-79.37%
ROE(3y)-56.17%
ROE(5y)-105.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NVIV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

The number of shares outstanding for NVIV has been increased compared to 1 year ago.
NVIV has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NVIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -38.75, we must say that NVIV is in the distress zone and has some risk of bankruptcy.
NVIV has a worse Altman-Z score (-38.75) than 92.93% of its industry peers.
NVIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.75
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 14.22 indicates that NVIV has no problem at all paying its short term obligations.
With an excellent Current ratio value of 14.22, NVIV belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
A Quick Ratio of 14.22 indicates that NVIV has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 14.22, NVIV belongs to the top of the industry, outperforming 95.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.22
Quick Ratio 14.22

0

3. Growth

3.1 Past

NVIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.05%, which is quite impressive.
EPS 1Y (TTM)56.05%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q56.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

NVIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

NVIV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

INVIVO THERAPEUTICS HOLDINGS

NASDAQ:NVIV (2/12/2024, 7:01:31 PM)

After market: 0.231 -0.09 (-27.97%)

0.3207

-0.17 (-34.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap997.38K
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.39%
ROE -104.6%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 14.22
Quick Ratio 14.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)56.05%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y